NCT05718700进行中（未招募）不适用
A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 170
- 试验地点
- 52
- 主要终点
- Exposure-adjusted Incidence of Participants With Liver-related Event: Hepatic Decompensation, Hepatocellular Carcinoma (HCC), Liver Transplantation, and Liver-related Death
研究概览
简要总结
The main goal of this study is to collect post marketing data from patients with chronic hepatitis D virus (HDV) infection who are treated with bulevirtide to describe the long-term effects of bulevirtide treatment and evaluate the safety of participants treated with bulevirtide.
详细描述
The study design time perspective is retrospective and prospective for participants who previously participated in MYR-Reg-02 and are currently receiving BLV and prospective for participants who are scheduled to receive BLV.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Individuals who have been diagnosed with chronic hepatitis D virus (HDV) infection for at least 6 months before study enrollment, confirmed by respective documentation in the individuals' medical records.
- •Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
- •Must be willing and able to comply with the visit schedule and study requirements.
- •Cohort 1 only: Must have participated in study MYR-Reg-
- •Cohort 2 only: Individuals scheduled to receive bulevirtide (BLV) according to the approved label or for whom the decision to start treatment with BLV according to the approved label has been made and treatment initiation is planned.
排除标准
- •Individuals currently enrolled in BLV clinical treatment studies and/or other interventional clinical studies with an investigational agent.
- •History or current presence of clinically significant illness or any other major medical disorder that may interfere with individual follow-up, assessments, or compliance with the protocol.
- •Coinfection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV) (Individuals with HCV antibodies can be enrolled if HCV RNA is negative).
- •Solid organ transplantation.
- •Any history, or current evidence of clinical hepatic decompensation (ie, ascites, encephalopathy, jaundice, or gastrointestinal bleeding (GIB)).
- •Presence of hepatocellular carcinoma (HCC) as evidenced by imaging (eg, ultrasound or computed tomography scan) performed within 4 months prior to Day 1 for individuals with cirrhosis and within 6 months prior to Day 1 for individuals without cirrhosis.
- •Pregnant or breastfeeding females.
- •Individuals with a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed by a positive polymerase chain reaction test result.
- •Known hypersensitivity or contraindication to BLV or formulation excipients.
- •Individuals who are committed to an institution by virtue of a court or official order.
- •Individuals deemed by the study investigator to be inappropriate for study participation for any reason not otherwise listed. This includes persons dependent on the sponsor, investigator, or trial site.
- •Note: Other protocol defined Inclusion/Exclusion criteria may apply.
研究组 & 干预措施
Bulevirtide (previously participated in Study MYR-Reg-2)
Participants who are currently receiving bulevirtide (BLV) according to the approved label and have participated in Study MYR-Reg-02.
干预措施: Bulevirtide (Drug)
Bulevirtide
Participants who are scheduled to receive BLV according to the approved label.
干预措施: Bulevirtide (Drug)
结局指标
主要结局
Exposure-adjusted Incidence of Participants With Liver-related Event: Hepatic Decompensation, Hepatocellular Carcinoma (HCC), Liver Transplantation, and Liver-related Death
时间窗: Up to 144 weeks
次要结局
- Percentage of Participants With Discontinuations Due to AEs(First dose date up to 144 weeks plus 30 days)
- Percentage of Participants With Serious Adverse Events(First dose date up to 144 weeks plus 30 days)
- Percentage of Participants With Grade 3 or 4 Adverse Events (AEs)(First dose date up to 144 weeks plus 30 days)
- Percentage of Participants Who Develop Cirrhosis During The Study Among Participants Who Were Previously Noncirrhotic(Up to 144 weeks)
研究者
研究点 (52)
Loading locations...
相似试验
招募中
不适用
HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLVHepatitis DNCT05928000University of Athens80
已完成
不适用
Post-market Assessment of Biodesign Dural Repair GraftsCerebrospinal Fluid LeakNCT04057157Cook Research Incorporated128
招募中
不适用
HBsAg Declined Patients Follow-up StudyHepatitis B, ChronicHepatitis BNCT05977283Nanfang Hospital, Southern Medical University100
已完成
不适用
To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated VesselsCoronary DiseaseCoronary RestenosisCoronary Artery DiseaseNCT01977534Abbott Medical Devices1,005
已完成
不适用
Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 TrialHepatitis BNCT00362674Bukwang Pharmaceutical